Colombia authorizes to use Cuba´s CIMAher anti-cancer drug

Havana, Dec 29 (Prensa Latina) Colombia´s Health and Protection Minister has authorized the inclusion of Cuba´s monoclonal antibody nimotuzumab (CIMAher) in its Domestic Benefit Plan, an official source reported Wednesday.

December 29, 2021
19:14

This decision allows Colombian doctors to prescribe the brand-new drug, Cuba´s Business Group of the Biotechnology and Pharmaceutical Industries (BioCubaFarma, in Spanish) posted on Twitter.

The monoclonal antibody nimotuzumab (CIMAher), developed and produced by the Center for Molecular Immunology (CIM, in Spanish), is registered as a combination therapy with radiation therapy or chemotherapy to fight advanced-stage squamous cell cancer of head and neck.

The new product can be also prescribed for patients suffering from Gioblastoma multiforme and astrocytoma, children with high-grade glioma, esophageal, advanced non-small cell lung and locally advanced pancreatic cancer.

Since 2002, CIMAher has been registered in Cuba for being used in separate clinical trials in several nations, by guaranteeing its effectiveness and safety.

mh/pll/msm/znc